Jennifer K Trittmann1, Eric Peterson2, Lynette K Rogers3, Bernadette Chen3, Carl H Backes4, Mark A Klebanoff5, Leif D Nelin3. 1. The Research Institute at Nationwide Children's Hospital, Columbus, OH; Pulmonary Hypertension Group, Center for Perinatal Research, The Research Institute at Nationwide Children's Hospital, Columbus, OH; Department of Pediatrics, The Ohio State University, Columbus, OH. Electronic address: Jennifer.Trittmann@nationwidechildrens.org. 2. Department of Pediatrics, The Ohio State University, Columbus, OH. 3. The Research Institute at Nationwide Children's Hospital, Columbus, OH; Pulmonary Hypertension Group, Center for Perinatal Research, The Research Institute at Nationwide Children's Hospital, Columbus, OH; Department of Pediatrics, The Ohio State University, Columbus, OH. 4. The Research Institute at Nationwide Children's Hospital, Columbus, OH; Pulmonary Hypertension Group, Center for Perinatal Research, The Research Institute at Nationwide Children's Hospital, Columbus, OH; Department of Pediatrics, The Ohio State University, Columbus, OH; The Heart Center at Nationwide Children's Hospital, Columbus, OH. 5. The Research Institute at Nationwide Children's Hospital, Columbus, OH; Department of Pediatrics, The Ohio State University, Columbus, OH.
Abstract
OBJECTIVE: To test the hypothesis that levels of the endogenous inhibitor of nitric oxide production, asymmetric dimethylarginine (ADMA), would be greater in preterm infants with bronchopulmonary dysplasia (BPD)-associated pulmonary hypertension (PH) than in infants with BPD alone. STUDY DESIGN: A case-control study of 23 patients with both BPD and PH (cases) and 95 patients with BPD but no evidence of PH (controls). Levels of ADMA were compared between cases and controls by t test. RESULTS: Patients with both BPD and PH had greater plasma levels of ADMA than patients with BPD alone (P = .04). In samples drawn before 28 days of life, greater levels of ADMA were again found in cases compared with controls (P = .02). The plasma arginine-to-ADMA ratio was lower in cases than in controls (P = .03), suggesting a greater likelihood of inhibition of nitric oxide production in patients with both BPD and PH than in patients with BPD alone. CONCLUSION: In this neonatal BPD cohort, ADMA levels are increased in patients with BPD who develop PH. We speculate that ADMA may be both a biomarker and a potential therapeutic target for preterm infants with BPD-associated PH.
OBJECTIVE: To test the hypothesis that levels of the endogenous inhibitor of nitric oxide production, asymmetric dimethylarginine (ADMA), would be greater in preterm infants with bronchopulmonary dysplasia (BPD)-associated pulmonary hypertension (PH) than in infants with BPD alone. STUDY DESIGN: A case-control study of 23 patients with both BPD and PH (cases) and 95 patients with BPD but no evidence of PH (controls). Levels of ADMA were compared between cases and controls by t test. RESULTS:Patients with both BPD and PH had greater plasma levels of ADMA than patients with BPD alone (P = .04). In samples drawn before 28 days of life, greater levels of ADMA were again found in cases compared with controls (P = .02). The plasma arginine-to-ADMA ratio was lower in cases than in controls (P = .03), suggesting a greater likelihood of inhibition of nitric oxide production in patients with both BPD and PH than in patients with BPD alone. CONCLUSION: In this neonatal BPD cohort, ADMA levels are increased in patients with BPD who develop PH. We speculate that ADMA may be both a biomarker and a potential therapeutic target for preterm infants with BPD-associated PH.
Authors: Marlieke Visser; Walter J Paulus; Mechteld A R Vermeulen; Milan C Richir; Mariska Davids; Willem Wisselink; Bas A J M de Mol; Paul A M van Leeuwen Journal: Eur J Heart Fail Date: 2010-10-05 Impact factor: 15.534
Authors: Clifford L Cua; Lynette K Rogers; Louis G Chicoine; Molly Augustine; Yi Jin; Patricia L Nash; Leif D Nelin Journal: Eur J Pediatr Date: 2010-12-01 Impact factor: 3.183
Authors: D L Pearson; S Dawling; W F Walsh; J L Haines; B W Christman; A Bazyk; N Scott; M L Summar Journal: N Engl J Med Date: 2001-06-14 Impact factor: 91.245
Authors: Hyo Soon An; Eun Jung Bae; Gi Beom Kim; Bo Sang Kwon; Jae Suk Beak; Ee Kyung Kim; Han Suk Kim; Jung-Hwan Choi; Chung Il Noh; Yong Soo Yun Journal: Korean Circ J Date: 2010-03-24 Impact factor: 3.243
Authors: Adolf Koudelka; Gabriela Ambrozova; Anna Klinke; Tana Fidlerova; Hana Martiskova; Radek Kuchta; Tanja K Rudolph; Jaroslav Kadlec; Zdenka Kuchtova; Steven R Woodcock; Bruce A Freeman; Lukas Kubala; Michaela Pekarova Journal: Cardiovasc Drugs Ther Date: 2016-12 Impact factor: 3.727
Authors: Jennifer K Trittmann; Markus Velten; Kathryn M Heyob; Hanadi Almazroue; Yi Jin; Leif D Nelin; Lynette K Rogers Journal: Clin Exp Pharmacol Physiol Date: 2018-02-06 Impact factor: 2.557
Authors: Shabih U Hasan; Jim Potenziano; Girija G Konduri; Jose A Perez; Krisa P Van Meurs; M Whit Walker; Bradley A Yoder Journal: JAMA Pediatr Date: 2017-11-01 Impact factor: 16.193
Authors: Jennifer K Trittmann; Julie M Gastier-Foster; Erik J Zmuda; Jessica Frick; Lynette K Rogers; Veronica J Vieland; Louis G Chicoine; Leif D Nelin Journal: Acta Paediatr Date: 2016-01-11 Impact factor: 2.299